Latest Communications

19 March 2012
Nautlius Neurosciences, Inc. Announces a New Approval for CAMBIA® in the Acute Treatment of Migraine

01 March 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of Zolmitriptan Oral Dispersible Film (ODF)

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.



APR Applied Pharma Research s.a.


info@apr.ch



Via Corti 5, CH - 6828 Balerna, 
Switzerland
Phone: +41 91 6957020


APR Applied Pharma Research USA, LLC


info@apr.ch


4401 Barclay Downs Drive - Ste. 105 Charlotte, 
NC 28209
Phone: (704) 365-3232



Search results